|
rs113488022
|
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Hence, recent research efforts have been performed trying to explore several inhibitors of the V600E mutation-containing BRAF kinase as potential therapeutic options in thyroid cancer refractory to standard interventions.
|
30481266 |
2019 |
|
rs113488022
|
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Furthermore, glycolysis-related enzymes, such as LDHA and PKM2, were upregulated in BRAF V600E </span>mutant thyroid cancer specimens, thereby promoting glycolysis.
|
30768848 |
2019 |
|
rs113488022
|
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E mutations are common in papillary thyroid carcinoma (PTC) and some de-differentiated thyroid cancers.
|
31529211 |
2019 |
|
rs113488022
|
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
In thyroid cancer, TPO expression is decreased partly by the BRAF(V600E) mutation, with direct impact on significant hormone production.
|
30742860 |
2019 |
|
rs113488022
|
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
We demonstrate detection of hallmark BRAF V600E mutations by NGS within infarcted tissue of thyroid carcinomas after FNA.
|
29868707 |
2018 |
|
rs113488022
|
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
<i>BRAF</i> V600E mutations have been successfully treated with targeted therapy in melanoma, non-small cell lung cancer, and thyroid cancer.
|
29295876 |
2018 |
|
rs113488022
|
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
These data support the role of IL6/STAT3 signaling pathway in modulating TC cell response to PLX4032 and candidate IL6 targeting as a strategy to improve the activity of PLX4032 in BRAF V600E TC cells.
|
29969659 |
2018 |
|
rs113488022
|
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
In summary, the present study demonstrated that thyroid cancer harboring the BRAF V600E mutation was resistant to a selective BRAF inhibitor due to reactivation of the MAPK pathway.
|
29616135 |
2018 |
|
rs113488022
|
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations.
|
30036146 |
2018 |
|
rs113488022
|
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Utility of the BRAF p.V600E immunoperoxidase stain in FNA direct smears and cell block preparations from patients with thyroid carcinoma.
|
29579361 |
2018 |
|
rs113488022
|
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The BRAF V600E mutation was detected in the PTCs of the two patients with thyroid cancer.
|
29593792 |
2018 |
|
rs113488022
|
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
TERT promoter mutations were likely to occur in BRAF V600E positive TC.
|
30024548 |
2018 |
|
rs113488022
|
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
This represents a novel mechanism in BRAF V600E-promoted PTC aggressiveness and identifies WIPF1 as a novel therapeutic target for thyroid cancer.
|
27863429 |
2017 |
|
rs113488022
|
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Acquired resistance to BRAF inhibition induces epithelial-to-mesenchymal transition in BRAF (V600E) mutant thyroid cancer by c-Met-mediated AKT activation.
|
27880942 |
2017 |
|
rs113488022
|
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The BM probe not only enabled sensitive detection of two types of EGFR-associated point mutations located in GC-rich regions, but also successfully identified the BRAF V600E mutation in the serum from a thyroid cancer patient which could not be detected by the conventional sequencing method.
|
28201758 |
2017 |
|
rs113488022
|
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
By contrast, evidences about sensitivity of thyroid carcinomas to BRAF inhibition are conflicting and it has been proposed that BRAF V600E thyroid carcinoma</span> cells are less sensitive to BRAF inhibitors due to activation of parallel signaling pathways.
|
29033690 |
2017 |
|
rs113488022
|
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
In this study, we investigated the relationship between the TME and thyroid cancer progression in a mouse model where thyroid-specific expression of oncogenic BRAF and loss of Pten (Braf(V600E)/Pten(-/-)/TPO-Cre) leads to papillary thyroid cancers (PTC) that rapidly progress to poorly differentiated thyroid cancer (PDTC).
|
26818109 |
2016 |
|
rs113488022
|
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Thus, TERT with promoter mutations represents a prominent new oncogene in thyroid cancer and the mutations are promising new diagnostic and prognostic genetic markers for thyroid cancer, which, in combination with BRAF V600E mutation or other genetic markers (e.g.
|
26733501 |
2016 |
|
rs113488022
|
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Given the strong genotype:phenotype correlation known to be present in thyroid cancer, the separation of BRAF(V600E)-like and RAS-like tumors has profound implications for its classification, especially the follicular variant of papillary carcinoma.
|
26569424 |
2016 |
|
rs113488022
|
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Inhibition of BRAF kinase suppresses cellular proliferation, but not enough for complete growth arrest in BRAF V600E mutated papillary and undifferentiated thyroid carcinomas.
|
27179656 |
2016 |
|
rs113488022
|
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
c-Met-mediated reactivation of PI3K/AKT signaling contributes to insensitivity of BRAF(V600E) mutant thyroid cancer to BRAF inhibition.
|
26456083 |
2016 |
|
rs113488022
|
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Genetic alterations occurring in thyroid cancer frequently affect the RAS/RAF/MEK/ERK-pathway such as the oncogenic, kinase-activating BRAF(V600E) mutation.
|
26892809 |
2016 |
|
rs113488022
|
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The CVF approach identified single-mutation driver candidates, such as BRAF V600E in the thyroid cancer dataset.
|
26543077 |
2016 |
|
rs113488022
|
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E mutation, RET rearrangements, and RAS mutations are the common genetic alterations in differentiated thyroid carcinomas derived from follicular thyroid cells.
|
27264674 |
2016 |
|
rs113488022
|
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The presence of BRAF V600E mutation in FNAC material is always associated with the presence of TC.
|
26884114 |
2016 |